BRD2 and cyclic hematopoiesis: In our studies, we focused on cognitively healthy (CH) participants aged 60 and older with either a pathological (CH-PAT) or normal (CH-NAT) β42-amyloid/tau ratio within the cerebrospinal fluid (CSF) (Harrington et al., 2013).